ABSTRACT
Introduction Tacrolimus is an immunosuppressant used extensively in solid organ transplantation. Whilst highly effective in preventing organ rejection, it has a narrow range of safe and effective concentrations and wide pharmacokinetic variability, which can lead to incomplete effectiveness, toxicities and suboptimal outcomes. Yet much is known about this pharmacokinetic variability. Tacrolimus is metabolised by cytochrome P450 (CYP) 3A4 and CYP3A5, with a clear link between pharmacogenetic variants and dose requirement. With additional patient covariates, more than 40% of tacrolimus’ pharmacokinetic variability can be explained. Individualisation of initial dose can increase proportion of transplant recipients within the acceptable range of concentrations in the initial post-transplant week, and subsequent maximum a posteriori Bayesian dosing can increase time in acceptable range over time, with potential to improve patient outcomes.
Method and analysis BRUNO-PIC is an open-label trial with a prospective intervention arm and a retrospective standard of care comparator arm. The prospective arm evaluates covariate-informed initial doses followed by Bayesian dose adjustment in children undergoing kidney, liver or heart transplant. A CYP3A5 and CYP3A4 genotype will be combined with allometric size scaling to predict initial tacrolimus doses. Post-transplant dose adjustment will be guided by NextDose, a Bayesian dosing platform that incorporates genotype, clinical characteristics, measured tacrolimus concentrations and a population pharmacokinetic model to maximally inform initial doses and dose adjustment recommendations over the first 8-weeks post-transplant. The co-primary outcome is the proportion of cohort with measured tacrolimus concentration within 80-125% of target, at post-transplant dosing day 4 (Ctrough), and day 4 at week 3 and week 8 (Cavgss target) post-transplant. The secondary outcomes include median time to acceptable range and the time in the acceptable range over the first 8-weeks post-transplant.
Ethics and dissemination The ethics approval of the trial has been obtained from the Sydney Children’s Ethics Committee (2023/ETH02699). Findings will be disseminated through peer-reviewed publications and professional conference presentations.
Trial registration: ClinicalTrials.gov NCT 06529536
Strengths This study integrates pre-transplant combined CYP3A5/3A4 genotyping and post-transplant Bayesian individualised dosing in paediatric solid organ transplant recipients, using concentration guided dosing techniques to improve exposure control.
Use of a target concentration approach based on average steady state concentrations is expected to reduce underexposure in individuals with high relative tacrolimus clearance (e.g. CYP3A5 expressers).
Limitations This paediatric solid organ transplant study may not be generalisable to all solid organ transplant patients.
Lack of randomised comparator arm precludes unconfounded determination of superiority over standard care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is funded by the 2023 Medical Research Future Fund, Genomics Health Future Mission (MRF/2024900)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Sydney Childrens Ethics Committee gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
One of the authors removed from manuscript. No changes to the supplement files or figures previously submitted
Data Availability
All data produced in the present study are available upon reasonable request to the authors
